Control Bionics (ASX:CBL) Gross-Profit-to-Asset % : 38.37% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Control Bionics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Control Bionics's annualized Gross Profit for the quarter that ended in Dec. 2024 was A$3.43 Mil. Control Bionics's average Total Assets over the quarter that ended in Dec. 2024 was A$8.93 Mil. Therefore, Control Bionics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 38.37%.

Control Bionics Gross-Profit-to-Asset % Historical Data

The historical data trend for Control Bionics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Control Bionics Gross-Profit-to-Asset % Chart

Control Bionics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Gross-Profit-to-Asset %

13.62

15.11

31.66

41.45

Control Bionics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				25.16	39.82	46.49	36.18	38.37

Competitive Comparison of Control Bionics's Gross-Profit-to-Asset %

For the Medical Devices subindustry, Control Bionics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Control Bionics's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Control Bionics's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Control Bionics Gross-Profit-to-Asset % Calculation

Control Bionics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: Jun. 2023 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=	3.673	/	( (8.696	+	9.027)	/ 2 )
	=	3.673	/	8.8615
	=	41.45 %

Control Bionics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	3.428	/	( (9.027	+	8.84)	/ 2 )
	=	3.428	/	8.9335
	=	38.37 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Control Bionics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Control Bionics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Control Bionics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Control Bionics Ltd (ASX:CBL) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121

Website

https://www.controlbionics.com

Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically it derives a majority of revenue from North America and has its presence in Australia as well.